- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Ovarian, fallopian tube, or primary peritoneal cancer
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1933KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 863KB)
Niraparib – March 2021
Niraparib: Capsule 100 mg; Zejula®
Last updated
16 July 2021